FilingReader Intelligence
Japan Tobacco exits pharma with Shionogi deal, focuses on core
May 7, 2025 at 12:03 PM UTC•By FilingReader AI
Japan Tobacco (TSE:2914) is exiting the pharmaceutical sector, transferring its business to Shionogi & Co., Ltd., through a simplified absorption-type split slated for December. JT's decision aims to optimize its core strengths and unlock shareholder value. As part of this strategic realignment, JT has also agreed to transfer its stake in Torii Pharmaceutical to Shionogi following Shionogi's tender offer, with JT not participating in the offer.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Consolidated Financial Results for the Three Months Ended March 31,2025 <under IFRS>May 7, 2025 at 06:33 AM UTC
Summary of financial results for the first quarter of the fiscal year ending December 2025 [IFRS] (consolidated)May 7, 2025 at 06:33 AM UTC
Notice regarding change in consolidated subsidiary (transfer of subsidiary shares)May 7, 2025 at 06:33 AM UTC
2025 First Quarter Results (CFO Presentation)May 7, 2025 at 06:33 AM UTC
Notice regarding the transfer of JT Group’s Pharmaceutical Business through a company simplified absorption-type splitMay 7, 2025 at 06:33 AM UTC
Notice of Change in Consolidated Subsidiary (Transfer of Subsidiary Shares)May 7, 2025 at 06:33 AM UTC
TSE:2914•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Japan Tobacco publishes news
Free account required • Unsubscribe anytime